AG1

Ownership

Public

Stage

Commercial

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

MultivitaminProbioticPrebioticAdaptogen blend

AG1 General Information

AG1’s flagship product is a daily health drink clinically shown to improve key nutrient biomarkers (e.g., RBC folate and vitamin C), enrich the gut microbiome with healthy bacteria, and close common nutrient gaps. These results are supported by multiple randomized placebo-controlled clinical trials in healthy adults. The latest formula ("AG1 Next Gen") includes five clinically studied probiotic strains and an enhanced methylated B complex.

Contact Information

Website

https://cag.gov.in/ag1/odisha/en

Primary Industry

Food & Nutrition

Corporate Office

,
United States

Drug Pipeline

AG1

Commercial

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to AG1's pipeline data

Book a demo

Key Partnerships

Costco – retail distribution partnership announced May 2025 for nationwide US availability.

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

AG1 Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view AG1's complete valuation and funding history, request access »

AG1 Financial Metrics

Market Cap

$1614.5M

Total Revenue

$3304.3M

Enterprise Value

$11188.1M